Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring
Qunrui Ye1, De-Gang Song1, Daniel J Powell2
1Ovarian Cancer Research Center; Department of Obstetrics and Gynecology; Perelman School of Medicine; University of Pennsylvania; Philadelphia, PA USA.
Oncoimmunology
|February 7, 2014
Abstract:
We have recently identified tumor necrosis factor receptor superfamily, member 9 (TNFRSF9, best known as CD137 or 4-1BB) as a biomarker of tumor-reactive T cells naturally occurring in cancer patients, and developed a rapid, accurate system to comprehensively isolate lymphocytes with tumor-rejecting properties from human biopsies. Our findings reveal a previously unappreciated role for CD137, a co-stimulatory TNFR family member, in the immunobiology of human cancer.
Keywords:
4-1BBCD137, adoptive immunotherapy, enrichment, tumor-associated antigens, tumor-infiltrating lymphocytesMore Related Videos
Related Concept Videos
01:22T Cell Activation and Clonal Selection
13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K